|
【结 构 式】 
|
【分子编号】54467 【品名】(6-ethoxy-6-oxohexyl)(triphenyl)phosphonium bromide 【CA登记号】 |
【 分 子 式 】C26H30BrO2P 【 分 子 量 】485.400762 【元素组成】C 64.34% H 6.23% Br 16.46% O 6.59% P 6.38% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(II)The Wittig condensation of 1-[4-(tert-butyldiphenylsilyloxymethyl)phenyl]-1-(3-pyridyl)methanone (I) with phosphonium bromide (II) by means of NaH in tert-butanol gives the heptenoic ester (III), which is desilylated with TBAF in THF to yield 7-[4-(hydroxymethyl)phenyl]-7-(3-pyridyl)-6-heptenoic acid ethyl ester (IV). The reaction of (IV) with Ms-Cl and TEA affords the corresponding mesylate (V), which is finally condensed with the triazolodiazepine (VI) by means of K2CO3 and 18-crown-6 in DMF.
| 【1】 Fujita, M.; et al.; Novel agents combining platelet activating factor (PAF) receptor antagonist with thromboxane synthase inhibitor (TxSI). Bioorg Med Chem Lett 2002, 12, 5, 771. |
| 【2】 Sano, T.; Seki, T.; Fujita, M.; Inada, H. (Nikken Chemicals Co., Ltd.); Triazolo-1,4-diazepine cpds. and medicinal compsn. containing the same. EP 0995752; JP 1999071378; US 6433167; WO 9858930 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 54466 | [4-({[tert-butyl(diphenyl)silyl]oxy}methyl)phenyl](3-pyridinyl)methanone | C29H29NO2Si | 详情 | 详情 | |
| (II) | 54467 | (6-ethoxy-6-oxohexyl)(triphenyl)phosphonium bromide | C26H30BrO2P | 详情 | 详情 | |
| (III) | 54468 | ethyl (E)-7-[4-({[tert-butyl(diphenyl)silyl]oxy}methyl)phenyl]-7-(3-pyridinyl)-6-heptenoate | C37H43NO3Si | 详情 | 详情 | |
| (IV) | 54469 | ethyl (E)-7-[4-(hydroxymethyl)phenyl]-7-(3-pyridinyl)-6-heptenoate | C21H25NO3 | 详情 | 详情 | |
| (V) | 54470 | ethyl (E)-7-(4-{[(methylsulfonyl)oxy]methyl}phenyl)-7-(3-pyridinyl)-6-heptenoate | C22H27NO5S | 详情 | 详情 | |
| (VI) | 14057 | 6-(2-Chlorophenyl)-1,4-dimethyl-7,8,9,10-tetrahydro-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine | C19H18ClN5S | 详情 | 详情 |
Extended Information